Overview

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of benmelstobart in combination with anlotinib and chemotherapy sequential benmelstobart in combination with anlotinib for the first-line treatment of extensive-stage small cell lung cancer.

Phase:

PHASE4

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

anlotinib
Carboplatin
Cisplatin
Etoposide